HopeStage
Back to all studies
CompletedNCT07173439

Multi-center, Single Blinded, RCT, Pivotal Study to Evaluate the Efficacy and Safety of DTx to Improve ADHD

Device studyAges 6–12South Korea
The study in practice

Understand this study

Who was this study for?

Listed age limits: 6 years to 12 years.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: April 15, 2024
Recruitment status
Completed
Enrollment listed in the registry
120
Sponsor
EMOTIV
Sponsor type
Unknown or unclear
Study type
Device
Intervention type
Device
Locations
South Korea
Age range
From 6 Years to 12 Years
Official registry ID
NCT07173439
Official title
Show the full official title

A Multi-center, Prospective, Single Blinded, Randomized, Comparative, Pivotal Clinical Trial to Evaluate the Efficacy and Safety of Digital Therapeutics to Improve ADHD Symptoms of Patients Diagnosed With ADHD

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Seoul

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is EMOTIV.

Who was this study for?

Listed age limits: 6 years to 12 years.

Want to explore more studies?

Explore studies